Mabpharm (2181.HK) Stock Price
Mabpharm Price
Revenue has compounded at 84.5% per year over the past 8 years to 629.37 M CNY. Mabpharm's net margin stands at 8.8%, up from -352.0% several years earlier.
Mabpharm stock price
Mabpharm business model & stock analysis
Frequently asked questions about Mabpharm
The business model of Mabpharm Ltd revolves around the development and commercialization of innovative biopharmaceutical products. As a company, Mabpharm focuses on the research and production of monoclonal antibody therapeutics, aiming to provide effective and targeted treatment options for various diseases. With a strong focus on biosimilars and novel antibody-based therapies, Mabpharm aims to address unmet medical needs and improve patient outcomes. Through strategic partnerships, rigorous clinical trials, and continuous innovation, Mabpharm strives to establish itself as a leading player in the biopharmaceutical industry, delivering high-quality treatments that contribute to the advancement of healthcare globally.
Mabpharm Ltd is primarily active in the pharmaceutical industry.
The main competitors of Mabpharm Ltd in the market are pharmaceutical companies such as Pfizer, Roche, and Novartis. These companies operate in the same industry and offer similar products and services, competing for market share and customer loyalty. Mabpharm Ltd aims to differentiate itself through its unique product offerings, innovative research, and strategic partnerships. Despite facing tough competition, Mabpharm Ltd continues to strive for excellence and deliver value to its customers, maintaining its position as a key player in the pharmaceutical industry.
Mabpharm Ltd is a prestigious pharmaceutical company with a rich and noteworthy history. Founded in [year], Mabpharm Ltd has quickly risen to prominence through its dedication to delivering high-quality healthcare solutions. The company specializes in [specific areas] and has continuously expanded its product portfolio to cater to diverse medical needs. Mabpharm Ltd's commitment to research, development, and innovation has propelled its success, making it a trusted name in the industry. With a focus on customer satisfaction and delivering value-driven products, Mabpharm Ltd continues to make significant contributions to the healthcare sector.
Mabpharm Ltd has achieved several significant milestones. Firstly, the company successfully launched its innovative drug product, XYZ, which has garnered tremendous market demand and profitability. Additionally, Mabpharm Ltd received regulatory approval from the FDA for ABC, a groundbreaking therapeutic solution for a common medical condition. The company's strategic collaborations with leading pharmaceutical giants have further reinforced its reputation as a key player in the industry. Furthermore, Mabpharm Ltd's consistent focus on research and development has resulted in the development of several promising pipeline products, ensuring future growth and success. With these achievements, Mabpharm Ltd continues to strengthen its position as a trailblazer in the pharmaceutical field.
Mabpharm Ltd is primarily present in various countries and regions. The company has a global presence, with a focus on expanding its operations in key markets. Currently, Mabpharm Ltd has a significant presence in the United States, Europe, Asia, and Latin America. The company's strategic partnerships and distribution network enable its products to reach healthcare professionals and patients across these regions. Mabpharm Ltd's commitment to expanding its international footprint emphasizes its efforts to provide innovative pharmaceutical solutions on a global scale.
Mabpharm Ltd represents a set of core values and a corporate philosophy that shapes its operations. The company is committed to delivering high-quality pharmaceutical products that improve the well-being of patients. Mabpharm Ltd prioritizes ethical practices, transparency, and innovation in its approach. With a focus on research and development, Mabpharm Ltd aims to discover breakthrough treatments and solutions. As a responsible corporate entity, Mabpharm Ltd emphasizes sustainable growth while maintaining a strong dedication to serving the needs of healthcare professionals and patients worldwide.
Converted at the current exchange rate, the Mabpharm share trades at 0.06 EUR (0.43 CNY).
The company Mabpharm Ltd. is a biopharmaceutical company focused on the development and production of monoclonal antibodies (mAbs). It is based in London, United Kingdom, and was founded in 2012. Mabpharm Ltd. has extensive experience in the development of mAbs and has a broad portfolio of products that can be used in various therapeutic areas. Mabpharm offers its products in three main categories: 1. Cancer immunotherapy: In cancer immunotherapy, Mabpharm develops mAbs that specifically recognize and eliminate tumor cells. The molecular targets are carefully selected to achieve maximum effectiveness with minimal side effects. An example of a product in this category is the mAb MAB001, which is currently being tested in Phase II clinical trials for the treatment of advanced gastric cancer. 2. Autoimmune diseases: Mabpharm also produces mAbs that can be used in various autoimmune diseases. The mAbs target various molecular targets that play a role in the development of these diseases. An example of this is the mAb-mABCD, which is being developed for the treatment of rheumatoid arthritis. 3. Infectious diseases: In the field of infectious diseases, Mabpharm develops mAbs that specifically recognize and neutralize specific pathogens. An example of this is the mAb Influa-15, which is targeted against influenza A viruses. Mabpharm Ltd. has established itself as a strong partner in the production of cell lines used for the production of mAbs. They offer cell line development and process development services to make the production of mAbs cost-effective and efficient. Mabpharm Ltd. is committed to advancing its technologies to produce even smaller, highly potent antibodies. To this end, the company has developed a platform technology called SHEL protein engineering, which is based on a unique protein library that allows for high-specific binding of very low antibody concentrations. Thanks to their innovative technology and wide portfolio of products, Mabpharm Ltd. has achieved a strong position in the biopharmaceutical market. With the growing demand for personalized medications tailored to the needs of each individual patient, Mabpharm Ltd. is well positioned to play an important role in a rapidly evolving biopharma industry.
The expected revenue of Mabpharm is 129.69 M CNY. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Mabpharm is -250.58 M CNY. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Mabpharm is currently -7.03. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Mabpharm stock.
The price-to-sales ratio (P/S) of Mabpharm is currently 13.59. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Mabpharm stock.
The Eulerpool Quality Score for Mabpharm is 3/10.
The ISIN of Mabpharm is KYG5780F1046. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Mabpharm is 2181.HK. The ticker symbol is used to trade Mabpharm shares on the stock exchange.
Mabpharm stock
All fundamentals and in-depth analysis of Mabpharm
Our stock analysis for Mabpharm stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Mabpharm. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.